MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: 22UA Forum: Aktien User: Thekla

Die Aussicht auf politischen Druck auf die Medikamentenpreise in den USA belastet die Branche, wobei der S&P 500 Pharmasektor um 2,2 Prozent nachgibt. US-Präsident Donald Trump fordert von großen Pharmakonzernen wie Eli Lilly, Novartis und Pfizer, dass Geringverdiener stärker von einer Bestpreisgarantie profitieren und neue Arzneien zum niedrigsten Preis angeboten werden. Quelle:Stock3

Das ist heute wirklich wieder Mal ein dicker Hund..Börse ist und bleibt überraschend

„So viel können die gar nicht saufen, wie die kotzen 🤮 müssten“ Zitat Ende. (Fußball) So gehts mir, wenn ich den Verlauf so verfolge!!!!

https://share.google/WUvVKDNFljiD2bHcw

Warum die Aktie von Bristol-Myers Squibb (BMY) heute niedriger gehandelt wird

Der Börsentag ( NTV) DAX Schlusskurs 🌏 https://www.n-tv.de/wirtschaft/der_boersen_tag/Der-Boersen-Tag-Donnerstag-31-Juli-2025-article25935932.html

https://share.google/cPmDtUpHjpw52ASEA

📰🗞finanzen.ch Das ist wohl der Grund für den Moderna Kurs: ,Moderna-Aktie im Minus: Moderna will sich von zehn Prozent der Angestellten trennen '' 31.07.25 .

Rudern auf sechzehntel? 🎶🎵

🕞NASDAQ START🕞 🔔9️⃣5️⃣,3️⃣5️⃣🔔

Moin 🍀 🌊🚢🤖🌏🌊🌂

🍻

Schlagzahl erhöhen 🍺 🍺 🍺 🍺 🍺

Hallo meine Lieben. Ausgugg ✅ Auf gehts BioNTech 🍀🍀🍀

🕞⛴️🌍🕊🌊⛴️ 👩🏼‍✈️👋🕞 Wir erhöhen mal die Schlagzahl!! 🚣🏼‍♀️🚣🏽‍♂️🚣🏼‍♀️🚣🏽‍♂️🚣🏼‍♀️

Teil 2- Q&A Analyst:“Hi, guys. Thank you so much for taking my question. I wanted to touch on some of the rationale for partnering with BioNTech and specifically what you saw their PD L1 VEGF bispecific? There's a lot of assets out there What attracted you to the partnership with them? Maybe walk me through some of the differentiation and how you can work with them to accelerate this to potentially be early kind of in the class of assets? Thank you.“ Bristol Myers representative: „Sure. Maybe I'll just say one word and then I'll turn it over to both Adam and Samit. First. As I mentioned in the prepared remarks, we're excited about the opportunity that we have with BioNTech. We think this is going to be a really value added partnership for us going forward. One of the things that was particularly attractive was this is an asset that is in a position to be either or second as this technology evolves. I mean, we know from our experience in immuno oncology with Opdivo, that that positioning in the marketplace is really important. And so that was one of the factors among many that attracted us to the BioNTech partnership. But maybe Adam, you and Samit can it up from there.“ „Yes. And just to build on what Adam just said, look, with two validated targets on a bispecific PD L1 and VEGF, the specificity of delivering the drug to the tumor because of expression of PD L1 that brings a differentiation compared to the PD-one VEGF inhibitors. Of course, we'll need to continue to watch out the evolution of the data across the tumor types that these drugs are being explored in. But certainly very excited to provide our help as well as support and the collaboration because of our footprint in 50 plus countries to conduct clinical trials. Initiation of the clinical trial certainly as Chris mentioned earlier is in small cell lung cancer, non small cell lung cancer and triple negative breast cancer. But there's a large CDP that is being built right now and we'll be able to share that later in the year. Right.“